International Biotechnology (LON:IBT) Shares Pass Above 200 Day Moving Average – Here’s Why

International Biotechnology (LON:IBT) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 690.81 ($8.54) and traded as high as GBX 733.88 ($9.07). International Biotechnology shares last traded at GBX 716 ($8.85), with a volume of 98,940 shares changing hands.

International Biotechnology Stock Up 1.5 %

The firm has a market capitalization of £268.68 million, a P/E ratio of 1,514.50 and a beta of 0.21. The stock has a fifty day moving average price of GBX 701.04 and a two-hundred day moving average price of GBX 690.81. The company has a debt-to-equity ratio of 9.66, a quick ratio of 0.32 and a current ratio of 0.46.

International Biotechnology Increases Dividend

The business also recently disclosed a dividend, which was paid on Friday, January 24th. Investors of record on Thursday, December 19th were paid a dividend of GBX 15.56 ($0.19) per share. This is an increase from International Biotechnology’s previous dividend of $14.50. This represents a yield of 2.21%. The ex-dividend date was Thursday, December 19th. International Biotechnology’s dividend payout ratio is presently 6,041.67%.

Insider Buying and Selling

In related news, insider Katherine Cornish-Bowden acquired 1,500 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was purchased at an average cost of GBX 713 ($8.81) per share, for a total transaction of £10,695 ($13,216.76). 4.18% of the stock is owned by company insiders.

International Biotechnology Company Profile

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.

The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.